Request for Comments on Ethical Considerations and Implications of Public Health Emergency Response With a Focus on the Current Ebola Virus Disease Epidemic, 72683 [2014-28617]
Download as PDF
Federal Register / Vol. 79, No. 235 / Monday, December 8, 2014 / Notices
Board of Governors of the Federal Reserve
System, December 3, 2014.
Michael J. Lewandowski,
Associate Secretary of the Board.
[FR Doc. 2014–28665 Filed 12–5–14; 8:45 am]
BILLING CODE 6210–01–P
FEDERAL RETIREMENT THRIFT
INVESTMENT BOARD
Sunshine Act; Notice of Meeting
10:00 a.m. (Eastern
Time) December 15, 2014 (Telephonic).
PLACE: 10th Floor Board Meeting Room,
77 K Street NE., Washington, DC 20002.
STATUS: Parts will be open to the public
and parts will be closed to the public.
MATTERS TO BE CONSIDERED:
TIME AND DATE:
Open to the Public
1. Approval of the Minutes of the
November 17, 2014 Board Member
Meeting
2. Thrift Savings Plan Monthly Reports
a. Monthly Participant Activity Report
b. Monthly Investment Policy Report
c. Legislative Report
3. Office of the General Counsel Update
Closed to the Public
4. Personnel
CONTACT PERSON FOR MORE INFORMATION:
Kimberly Weaver, Director, Office of
External Affairs, (202) 942–1640.
Dated: December 4, 2014.
James Petrick,
General Counsel, Federal Retirement Thrift
Investment Board.
[FR Doc. 2014–28844 Filed 12–4–14; 4:15 pm]
BILLING CODE 6760–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Request for Comments on Ethical
Considerations and Implications of
Public Health Emergency Response
With a Focus on the Current Ebola
Virus Disease Epidemic
Office of the Secretary,
Presidential Commission for the Study
of Bioethical Issues, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
The Presidential Commission
for the Study of Bioethical Issues is
requesting public comment on ethical
considerations and implications of
public health emergency response with
a focus on the current Ebola virus
disease epidemic.
DATES: To ensure consideration,
comments must be received by 5:00
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
20:19 Dec 05, 2014
Jkt 235001
p.m. EST on February 6, 2015.
Comments received after this date will
be considered only as time permits.
ADDRESSES: Individuals, groups, and
organizations interested in commenting
on this topic may submit comments by
email to info@bioethics.gov or by mail to
the following address: Public
Commentary, Presidential Commission
for the Study of Bioethical Issues, 1425
New York Ave. NW., Suite C–100,
Washington, DC 20005.
FOR FURTHER INFORMATION CONTACT:
Hillary Wicai Viers, Communications
Director, Presidential Commission for
the Study of Bioethical Issues.
Telephone: 202–233–3960. E-Mail:
hillary.viers@bioethics.gov. Additional
information may be obtained at https://
www.bioethics.gov.
SUPPLEMENTARY INFORMATION: On
November 24, 2009, the President
established the Presidential Commission
for the Study of Bioethical Issues (the
Commission) to advise him on
bioethical issues generated by novel and
emerging research in biomedicine and
related areas of science and technology.
The Commission is charged with
identifying and promoting policies and
practices that ensure ethically
responsible conduct of scientific
research and health care delivery.
Undertaking these duties, the
Commission seeks to identify and
examine specific bioethical, legal, and
social issues related to potential
scientific and technological advances;
examine diverse perspectives and
possibilities for international
collaboration on these issues; and
recommend legal, regulatory, or policy
actions as appropriate.
The Commission is considering three
areas of ethical concern raised by public
health emergency response with a focus
on the current Ebola virus disease (EVD)
epidemic. The first area concerns U.S.
public policies that restrict association
or movement (such as quarantine),
which have recently been proposed
and/or employed for health care
workers and military personnel
returning from countries affected by
EVD in western Africa. The second area
concerns the ethics of placebocontrolled trials in the context of public
health emergencies, and the EVD
epidemic specifically, where the drug
undergoing testing might be effective
against the disease causing the
emergency. The third area of concern is
the ethical considerations relevant to
collecting and storing biospecimens
during a public health emergency, such
as the EVD epidemic, and sharing these
specimens and associated data
internationally for future research. At its
PO 00000
Frm 00063
Fmt 4703
Sfmt 9990
72683
meeting on November 6, 2014, the
Commission heard from legal and
medical experts in public health and
infectious disease, and began its
consideration of the complex ethical
landscape of U.S. public health
emergency response to the EVD
epidemic.
The Commission is interested in
receiving comments from individuals,
groups, and professional communities
regarding the three areas of ethical
concern outlined above. The
Commission is particularly interested in
receiving public commentary regarding
the following issues in the context of
public health emergency response
generally and the EVD epidemic
specifically:
• Ethical and scientific standards for
public health emergency response;
• Ethical and scientific standards that
guide the use of quarantine or other
movement restrictions during public
health emergencies;
• The impact of quarantine or other
movement restrictions on the
availability or willingness of health
workers to volunteer to contain the
epidemic in disease-affected areas;
• The impact of quarantine or other
movement restrictions on public fear
and anxiety about potential threats to
public health;
• How U.S. public policy and public
health response to the current EVD
epidemic might or should affect public
attitudes to, and further U.S. policy and
public health response to, other current
and future public health issues and
emergencies;
• Ethical and scientific standards for
placebo-controlled trials during public
health emergencies;
• Ethical and scientific standards for
collection, storage, and international
sharing of biospecimens and associated
data during public health emergencies.
To this end, the Commission is
inviting interested parties to provide
input and advice through written
comments.
Comments will be publicly available,
including any personally identifiable or
confidential business information that
they contain. Trade secrets should not
be submitted.
Dated: November 20, 2014.
Lisa M. Lee,
Executive Director, Presidential Commission
for the Study of Bioethical Issues.
[FR Doc. 2014–28617 Filed 12–5–14; 8:45 am]
BILLING CODE 4154–06–P
E:\FR\FM\08DEN1.SGM
08DEN1
Agencies
[Federal Register Volume 79, Number 235 (Monday, December 8, 2014)]
[Proposed Rules]
[Page 72683]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-28617]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Request for Comments on Ethical Considerations and Implications
of Public Health Emergency Response With a Focus on the Current Ebola
Virus Disease Epidemic
AGENCY: Office of the Secretary, Presidential Commission for the Study
of Bioethical Issues, Office of the Secretary, Department of Health and
Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Presidential Commission for the Study of Bioethical Issues
is requesting public comment on ethical considerations and implications
of public health emergency response with a focus on the current Ebola
virus disease epidemic.
DATES: To ensure consideration, comments must be received by 5:00 p.m.
EST on February 6, 2015. Comments received after this date will be
considered only as time permits.
ADDRESSES: Individuals, groups, and organizations interested in
commenting on this topic may submit comments by email to
info@bioethics.gov or by mail to the following address: Public
Commentary, Presidential Commission for the Study of Bioethical Issues,
1425 New York Ave. NW., Suite C-100, Washington, DC 20005.
FOR FURTHER INFORMATION CONTACT: Hillary Wicai Viers, Communications
Director, Presidential Commission for the Study of Bioethical Issues.
Telephone: 202-233-3960. E-Mail: hillary.viers@bioethics.gov.
Additional information may be obtained at https://www.bioethics.gov.
SUPPLEMENTARY INFORMATION: On November 24, 2009, the President
established the Presidential Commission for the Study of Bioethical
Issues (the Commission) to advise him on bioethical issues generated by
novel and emerging research in biomedicine and related areas of science
and technology. The Commission is charged with identifying and
promoting policies and practices that ensure ethically responsible
conduct of scientific research and health care delivery. Undertaking
these duties, the Commission seeks to identify and examine specific
bioethical, legal, and social issues related to potential scientific
and technological advances; examine diverse perspectives and
possibilities for international collaboration on these issues; and
recommend legal, regulatory, or policy actions as appropriate.
The Commission is considering three areas of ethical concern raised
by public health emergency response with a focus on the current Ebola
virus disease (EVD) epidemic. The first area concerns U.S. public
policies that restrict association or movement (such as quarantine),
which have recently been proposed and/or employed for health care
workers and military personnel returning from countries affected by EVD
in western Africa. The second area concerns the ethics of placebo-
controlled trials in the context of public health emergencies, and the
EVD epidemic specifically, where the drug undergoing testing might be
effective against the disease causing the emergency. The third area of
concern is the ethical considerations relevant to collecting and
storing biospecimens during a public health emergency, such as the EVD
epidemic, and sharing these specimens and associated data
internationally for future research. At its meeting on November 6,
2014, the Commission heard from legal and medical experts in public
health and infectious disease, and began its consideration of the
complex ethical landscape of U.S. public health emergency response to
the EVD epidemic.
The Commission is interested in receiving comments from
individuals, groups, and professional communities regarding the three
areas of ethical concern outlined above. The Commission is particularly
interested in receiving public commentary regarding the following
issues in the context of public health emergency response generally and
the EVD epidemic specifically:
Ethical and scientific standards for public health
emergency response;
Ethical and scientific standards that guide the use of
quarantine or other movement restrictions during public health
emergencies;
The impact of quarantine or other movement restrictions on
the availability or willingness of health workers to volunteer to
contain the epidemic in disease-affected areas;
The impact of quarantine or other movement restrictions on
public fear and anxiety about potential threats to public health;
How U.S. public policy and public health response to the
current EVD epidemic might or should affect public attitudes to, and
further U.S. policy and public health response to, other current and
future public health issues and emergencies;
Ethical and scientific standards for placebo-controlled
trials during public health emergencies;
Ethical and scientific standards for collection, storage,
and international sharing of biospecimens and associated data during
public health emergencies.
To this end, the Commission is inviting interested parties to
provide input and advice through written comments.
Comments will be publicly available, including any personally
identifiable or confidential business information that they contain.
Trade secrets should not be submitted.
Dated: November 20, 2014.
Lisa M. Lee,
Executive Director, Presidential Commission for the Study of Bioethical
Issues.
[FR Doc. 2014-28617 Filed 12-5-14; 8:45 am]
BILLING CODE 4154-06-P